Page 42 - Read Online

Page 12 of 12 Armengol et al. Hepatoma Res 2021;7:50 https://dx.doi.org/10.20517/2394-5079.2021.19

BMC Cancer 2011;11:362. DOI PubMed PMC
56. Munoz M, Covenas R. The Neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers (Basel)
2020;12:2682. DOI PubMed PMC
57. Berger M, Neth O, Ilmer M, et al. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by
aprepitant in vitro and in vivo. J Hepatol 2014;60:985-94. DOI PubMed
58. Eberherr C, Beck A, Vokuhl C, et al. Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of
hepatoblastoma cells. Int J Oncol 2019;54:1853-63. DOI PubMed
59. Wagner AE, Schwarzmayr T, Haberle B, et al. SP8 promotes an aggressive phenotype in hepatoblastoma via FGF8 activation. Cancers
(Basel) 2020;12:2294. DOI PubMed PMC
60. Whitlock RS, Yang T, Vasudevan SA, Woodfield SE. Animal modeling of pediatric liver cancer. Cancers (Basel) 2020;12:273. DOI
PubMed PMC
61. Mokkapati S, Niopek K, Huang L, et al. beta-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular
carcinoma and hepatoblastoma. Cancer Res 2014;74:4515-25. DOI PubMed PMC
62. Bissig-Choisat B, Kettlun-Leyton C, Legras XD, et al. Novel patient-derived xenograft and cell line models for therapeutic testing of
pediatric liver cancer. J Hepatol 2016;65:325-33. DOI PubMed PMC
63. Nicolle D, Fabre M, Simon-Coma M, et al. Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and
advise clinical management. Hepatology 2016;64:1121-35. DOI PubMed
64. Kats D, Ricker CA, Berlow NE, et al. Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget 2019;10:6403-17. DOI
PubMed PMC
65. Yamada S, Ohira M, Horie H, et al. Expression profiling and differential screening between hepatoblastomas and the corresponding
normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene
2004;23:5901-11. DOI PubMed
66. Eloranta K, Cairo S, Liljestrom E, et al. Chloroquine triggers cell death and inhibits PARPs in cell models of aggressive
hepatoblastoma. Front Oncol 2020;10:1138. DOI PubMed PMC
67. Woodfield SE, Shi Y, Patel RH, et al. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep
2021;11:2967. DOI PubMed PMC